Transforming Cardiorenal Care: Nurse-Led Strategies for Heart Failure Management With SGLT2 Inhibitors

The goal of this activity is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Heart Failure.

• Identify gaps in heart failure management guideline-directed medical therapy to improve patient outcomes

• Assess the benefits and safety of early and long-term use of SGLT2 inhibitors in heart failure care, focusing on their role in improving cardiovascular outcomes for eligible patients

• Formulate nurse-led strategies to incorporate SGLT2 inhibitors into patient-centered treatment plans considering diverse presentations of left ventricular ejection fraction

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Midge Bowers, DNP, FNP-BC, FAANP, FAAN, FACC, has no relevant financial relationships to disclose.

Stephen J. Greene, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Corcept, CSL Vifor, Idorsia, Lexicon, Lilly, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Recordati, Sanofi, SCPharmaceuticals, Sumitomo, Tricog Health; researcher: Bayer, Boehringer Ingelheim, Novartis.